We propose to compare the effectiveness of the conventional high-throughput screening (HTS) approach with a new integrated ligand design strategy using computational modeling, biophysical NMR studies and biochemical assays. We will compare the effectiveness of these two approaches against two targets-a conventional kinase (B-Raf) and a challenging protein-protein interaction between K-Ras and B-Raf. K-Ras is an oncoprotein of paramount importance of cancer biology. The Ras oncoproteins (K-Ras, H-Ras, N-Ras) were discovered over 30 years ago, but have been resistant to direct targeting with small molecule drugs. Thus, despite the fact that the KRAS gene is mutated in ~20% of all tumors, and >60% of pancreatic cancers, there is no therapy for treating mutant KRAS tumors. K-Ras activation of effector proteins (Raf proteins, PI3K proteins, and Ral-GDS, among others) is mediated through the switch I region on K-Ras, which forms an extended beta sheet with the Ras-binding domain of B- Raf and other effector proteins. An antibody that disrupts this protein-protein interaction reverses Ras-induced tumor formation in animals. Thus, a small molecule inhibitor of this interaction is likely to be a useful therapeutic for tumors containing mutant KRAS. If we demonstrate increased effectiveness of this new design approach compared to standard HTS, it will have a profound effect on the likelihood of small molecule inhibitor discovery against currently undruggable target proteins. This project could thus lead to the first small molecule therapeutics for targeting tumors with mutant K-Ras and may open up a large number of undruggable targets to small molecule inhibition.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-2 (M1))
Program Officer
Li, Jerry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Other Domestic Higher Education
New York
United States
Zip Code
Viswanathan, Vasanthi S; Ryan, Matthew J; Dhruv, Harshil D et al. (2017) Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547:453-457
Welsch, Matthew E; Kaplan, Anna; Chambers, Jennifer M et al. (2017) Multivalent Small-Molecule Pan-RAS Inhibitors. Cell 168:878-889.e29
Shimada, Kenichi; Hayano, Miki; Pagano, Nen C et al. (2016) Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity. Cell Chem Biol 23:225-235
Yang, Wan Seok; Kim, Katherine J; Gaschler, Michael M et al. (2016) Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A 113:E4966-75
Hayano, M; Yang, W S; Corn, C K et al. (2016) Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ 23:270-8
Li, Hai; Kuwajima, Takaaki; Oakley, Derek et al. (2016) Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth. Cell Rep 16:545-558
Shimada, Kenichi; Skouta, Rachid; Kaplan, Anna et al. (2016) Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol 12:497-503
Yang, Wan Seok; Stockwell, Brent R (2016) Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol 26:165-176
Larraufie, Marie-Helene; Yang, Wan Seok; Jiang, Elise et al. (2015) Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. Bioorg Med Chem Lett 25:4787-92
Kaplan, Anna; Gaschler, Michael M; Dunn, Denise E et al. (2015) Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective. Proc Natl Acad Sci U S A 112:E2245-52

Showing the most recent 10 out of 26 publications